CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2024年12月1日～2024年12月7日の間に収集した論文情報を追加しました。

  1. Thromboembolic events associated with combined oral contraceptives: a real-world study based on the FDA adverse event reporting system (FAERS) database.

  経口避妊薬による血栓症リスクの分析

  対象DB：FAERS

  2. Association between cyclin-dependent kinase 4/6 inhibitors and nephrotoxicity in patients with breast cancer: A Systematic Review and meta-analysis.

  CDK4/6阻害薬の腎毒性リスクを解析

  対象DB：FAERS

  3. Signal detection and analysis of Sulfasalazine adverse reaction events based on the US FDA adverse event reporting database.

  スルファサラジンの副作用をFAERSで分析

  対象DB：FAERS

  4. Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system.

  アミオダロンの肺毒性リスクと新たなシグナルを確認

  対象DB：FAERS

  5. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration.

  スタチン使用で女性に糖尿病報告率が高い

  対象DB：FAERS

  6. Real-world safety evaluation of atorvastatin: insights from the US FDA adverse event reporting system (FAERS).

  アトルバスタチンの副作用解析、筋肉障害や糖尿病などが確認

  対象DB：FAERS

  7. Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database.

  タファミジスの副作用解析、腎尿路障害などが新たに発見

  対象DB：FAERS

  8. The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.

  シロスタゾールの副作用リスクをFAERSで解析

  対象DB：FAERS

  9. Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network.

  患者レベルの副作用予測を行う新手法「PreciseADR」

  対象DB：FAERS

  10. Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis.

  薬剤によるB型肝炎再活性化のリスクを検出

  対象DB：FAERS

  11. Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System.

  SGLT2阻害薬は心室性不整脈の報告頻度は同等、突然死は低い

  対象DB：FAERS

  12. Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database.

  セプルカチニブは食道炎や心嚢液、片麻痺など新たな副作用が報告

  対象DB：FAERS

  13. Exploring the dark side of diagnostic dyes with a focus on Indocyanine green's adverse reactions.

  インドシアニングリーンはショックや低血圧などの副作用がある

  対象DB：FAERS

  14. Data Mining and Analysis for Iodinated Contrast Media Adverse Event Signals Based on the Food and Drug Administration Adverse Event Reporting System Database.

  ヨウ素造影剤で呼吸器や皮膚に副作用が多い

  対象DB：FAERS

  15. Comparison of the pharmacovigilance signals of cardiac and renal adverse events associated with sacubitril/valsartan and valsartan alone based on the FAERS database.

  サクビトリル/バルサルタンはバルサルタンより腎臓リスクが高い

  対象DB：FAERS

  16. Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database.

  FAERSの重複報告検出方法と信頼性向上

  対象DB：FAERS

  17. Levetiracetam and severe cutaneous adverse reactions: insights from FAERS database analysis.

  レベチラセタムと重度皮膚反応の関連性調査

  対象DB：FAERS

  18. Adverse events of mepolizumab in the treatment of nasal polyps: A FDA database evaluation.

  メポリズマブによるCRSwNP治療の副作用と影響分析

  対象DB：FAERS

  19. Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system.

  転倒リスク増加薬の性別差に関する分析

  対象DB：FAERS

  20. Frequency of androgenic cutaneous adverse events associated with levonorgestrel intrauterine devices: An analysis of the Food and Drug Administration Adverse Event Reporting System database.

  レボノルゲストレルIUDに関連する皮膚副作用の頻度分析

  対象DB：FAERS

  21. A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.

  イルベサルタンの有害事象、新たなシグナルを確認

  対象DB：JADER

  22. A retrospective study of seasonal variation in sodium-glucose co-transporter 2 inhibitor-related adverse events using the Japanese adverse drug event report database.

  SGLT2阻害薬の有害事象に季節変動あり

  対象DB：JADER

  23. The Use of Botulinum Toxin Type A and the Occurrence of Anaphylaxis: A Descriptive Analysis of Data from the European Spontaneous Reporting System.

  ボツリヌス毒素Aによるアナフィラキシー反応の報告

  対象DB：EudraVigilance

  24. Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals.

  免疫チェックポイント阻害薬再投与で31.8%のirAE再発

  対象DB：VigiBase

  25. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.

  乾癬治療薬の妊娠中の安全性は、TNF-α阻害薬より良好

  対象DB：VigiBase

  26. Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database.

  ワクチンが慢性蕁麻疹を引き起こす可能性あり

  対象DB：VigiBase

  27. Global estimates of vaccine-associated hepatic autoimmune disorders and their related vaccines, 1968-2024: An international analysis of the WHO pharmacovigilance database.

  ワクチンが肝自己免疫疾患を引き起こす可能性あり

  対象DB：VigiBase

  28. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data.

  小児・青年のクロザピンによる致命的副作用は白血球減少以外にも多様

  対象DB：VigiBase

  29. Limited impact of weekend admissions on hip fracture outcomes in elderly patients: A study from a Japanese nationwide medical claims database.

  高齢者股関節骨折患者の週末入院は合併症や死亡リスクに影響なし

  対象DB：DPC

  30. Sex differences among sleep disordered breathing, obesity, and metabolic comorbidities; the Nagahama study.

  閉塞性睡眠時無呼吸症候群は、特に閉経前女性で肥満や代謝症候群と関連

  対象DB：JMDC

  31. Epidemiology of narcolepsy and idiopathic hypersomnia in Japan: A retrospective analysis of health insurance claims from the Japan Medical Data Center.

  ナルコレプシーと特発性過眠症の有病率と発生率を日本で推定

  対象DB：JMDC

  32. Impact of COVID-19 on paediatric care in Japan: Analysis of national health insurance claims data.

  COVID-19で小児医療利用が大幅に減少、年齢や診療種別で差

  対象DB：NDB

  33. Associations Between Sleep Satisfaction and Physical Activity Rates Among Secondary Medical Areas in Japan: An Ecological Study.

  日常活動と歩行速度が睡眠満足度に影響、個別指導が重要

  対象DB：NDB

  34. Risk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors.

  VEGF阻害薬は動脈解離リスクを増加させる可能性あり

  対象DB：NDB

  35. Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study.

  COPD治療でSITTはMITTより服薬遵守率が高い

  対象DB：MDV

  36. Long-term trends in English general practice consultation rates from 1995 to 2021: a retrospective analysis of two electronic health records databases.

  1995-2021年の診療記録から診療率の長期的変化を分析

  対象DB：CPRD

  37. Inequalities in the prevalence recording of 205 chronic conditions recorded in primary and secondary care for 12 million patients in the English National Health Service.

  疾患記録は人種や地域で格差があり、連携改善が必要

  対象DB：CPRD

  38. Evaluating the quality of prostate cancer diagnosis recording in CPRD GOLD and CPRD Aurum primary care databases for observational research: A study using linked English electronic health records.

  前立腺癌診断の記録はAurumがGOLDより正確だが、連携推奨

  対象DB：CPRD

  39. Differences in recording of cancer diagnosis between datasets in England: A population-based study of linked cancer registration, hospital, and primary care data.

  癌登録と電子記録の診断一致率は癌種で異なる

  対象DB：CPRD

  40. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.

  COVID-19ワクチン接種後の聴覚障害は早期検出可能だが、発生率は低い

  対象DB：FPVD

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み